Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 11/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | RAD52 | P43351 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | TOP2A | P11388 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.44 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.44 |
| ▸ | TERT | O14746 | 2/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14596189 | 0.92 | FLT3 (0.56) | FLT3ALDH1A1MAPK1RAD52KMT2A | |
| SCHEMBL14596203 | 0.89 | FLT3 (0.55) | FLT3ALDH1A1MAPK1RAD52KMT2A | |
| SCHEMBL14596217 | 0.89 | POLB (0.52) | FLT3ALDH1A1MAPK1RAD52KMT2A | |
| SCHEMBL14596213 | 0.87 | RAD52 (0.53) | FLT3ALDH1A1MAPK1RAD52KMT2A | |
| SCHEMBL14596204 | 0.86 | POLB (0.58) | FLT3ALDH1A1MAPK1RAD52KMT2A | |
| SCHEMBL14596188 | 0.86 | ALDH1A1 (0.49) | FLT3ALDH1A1MAPK1RAD52KMT2A | |
| SCHEMBL14596216 | 0.85 | MTOR (0.56) | FLT3ALDH1A1MAPK1RAD52KMT2A | |
| SCHEMBL14596221 | 0.85 | ALDH1A1 (0.47) | FLT3ALDH1A1MAPK1RAD52KMT2A | |
| SCHEMBL14596202 | 0.85 | POLB (0.51) | FLT3ALDH1A1MAPK1RAD52KMT2A | |
| SCHEMBL14596218 | 0.85 | POLB (0.48) | FLT3ALDH1A1MAPK1RAD52KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070015774-A1 | Quinazoline derivatives useful in cancer treatment | SCHERING CORPORATION | 2007-01-18 | — | — | US | disclosed |
| US-20070015774-A1 | Quinazoline derivatives useful in cancer treatment | SCHERING CORPORATION | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015774-A1 | Quinazoline derivatives useful in cancer treatment | TP53, TP53BP1, ACIN1 | FLT3 191/4885ALDH1A1 1994/4885MAPK1 2089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.